Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24878816)

  • 1. Predictive factors to targeted treatment in gastrointestinal carcinomas.
    Silvestris N; Marech I; Brunetti AE; Azzariti A; Numico G; Cicero G; Delcuratolo S; De Luca R; Burz C; Lorusso V
    Cancer Biomark; 2014; 14(2-3):151-62. PubMed ID: 24878816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
    Hawkes E; Cunningham D
    Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
    [No Abstract]   [Full Text] [Related]  

  • 4. Individualized therapy for metastatic colorectal cancer.
    Silvestri A; Pin E; Huijbers A; Pellicani R; Parasido EM; Pierobon M; Petricoin E; Liotta L; Belluco C
    J Intern Med; 2013 Jul; 274(1):1-24. PubMed ID: 23527888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer.
    Lu W; Wei H; Li M; Wang H; Liu L; Zhang Q; Liu L; Lu S
    Mol Med Rep; 2015 Jul; 12(1):1219-24. PubMed ID: 25815786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between colorectal cancer biomarkers and response to epidermal growth factor receptor monoclonal antibodies.
    Hawkes E; Cunningham D
    J Clin Oncol; 2010 Oct; 28(28):e529-31; author reply e532-e533. PubMed ID: 20679615
    [No Abstract]   [Full Text] [Related]  

  • 8. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.
    Dienstmann R; Tabernero J
    Cancer J; 2016; 22(3):149-55. PubMed ID: 27341591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
    Wong R; Cunningham D
    J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
    [No Abstract]   [Full Text] [Related]  

  • 11. The forest and the trees: pathways and proteins as colorectal cancer biomarkers.
    Bertagnolli MM
    J Clin Oncol; 2009 Dec; 27(35):5866-7. PubMed ID: 19884524
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictive biomarkers of clinical response to targeted antibodies in colorectal cancer.
    Chua W; Moore MM; Charles KA; Clarke SJ
    Curr Opin Mol Ther; 2009 Dec; 11(6):611-22. PubMed ID: 20072938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Progress of targeted therapy related to K-ras mutation].
    Li ZW; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
    [No Abstract]   [Full Text] [Related]  

  • 15. What can molecular pathology offer for optimal decision making?
    Aust DE; Sommer U; Baretton GB
    Ann Oncol; 2012 Sep; 23 Suppl 10():x63-70. PubMed ID: 22987994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A; Siena S
    J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
    De Roock W; De Vriendt V; Normanno N; Ciardiello F; Tejpar S
    Lancet Oncol; 2011 Jun; 12(6):594-603. PubMed ID: 21163703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
    Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.
    Caiazza F; Elliott L; Fennelly D; Sheahan K; Doherty GA; Ryan EJ
    Biomark Med; 2015; 9(4):363-75. PubMed ID: 25808440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS and BRAF: drug targets and predictive biomarkers.
    Vakiani E; Solit DB
    J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.